Right, let’s dive into the latest pulse check from Advanced Medical Solutions Group plc (AIM: AMS). Their half-year trading update for the six months ended 30 June 2025 landed today, and frankly, it’s the kind of update shareholders like to see – solid, confident, and showing tangible progress on strategic goals. No drama, just execution.
Stitching Together Strong Growth
The headline numbers are undeniably robust. AMS expects to report H1 2025 revenues of approximately £110 million. Let that sink in for a second. That’s a significant leap from the £68.0 million reported for the same period last year. Driving this? Continued strong underlying momentum in their core surgical product portfolio.
Profitability is keeping pace nicely. Adjusted EBITDA is guided to between £24.0 million and £24.5 million, comfortably up from H1 2024’s £18.2 million. Crucially, management states this performance is “in line with expectations,” and they remain “confident in meeting full-year consensus forecasts.” Confidence backed by momentum is a powerful signal.
The Integration Engine is Firing
This update wasn’t just about organic growth; it was a report card on recent acquisitions – specifically Peters Surgical (acquired July 2024) and Syntacoll.
- Progress is “progressing well”: Operational and strategic alignment is on track.
- Early Synergies Biting: This is the key takeaway. CEO Chris Meredith highlighted that “initial commercial synergies” from these integrations are already contributing positively to surgical sales growth. That’s faster value capture than often anticipated post-acquisition.
- Long-Term Focus: The team is “fully focused on delivering longer-term, significant synergies.” They’ve seen the early proof of concept and are now doubling down.
Meredith’s comment about it being “a good moment to take stock” one year after the Peters Surgical deal underscores a sense of satisfaction with how the pieces are fitting together.
Woundcare: Restructured and Ready
While surgical leads the charge, the previously flagged restructuring of the Woundcare business is now complete. The process finished by the end of March 2025, and the benefits are already flowing:
- Improved Margins: The update specifically notes that the restructuring has resulted in “improved margins for that business from the second quarter.”
- Steady Contribution: Management describes the restructured Woundcare unit as now entering “a new phase” and making a “steady contribution to the Group.” It sounds like this division has moved from being a drag to a dependable contributor.
The Path Ahead
Underpinned by the core surgical strength, the successful integration momentum, and a now-stabilised Woundcare division, AMS is clearly in growth mode. The tone from Meredith is one of pressing ahead: “we are pressing ahead to deliver strong growth at the Group level.”
Mark your calendars: The full interim results, providing the detailed financials and colour behind this update, will be announced on 17 September 2025.
Bottom Line
This is a straightforwardly positive update from AMS. They’ve delivered strong revenue and profit growth, crucially driven not just by market tailwinds but by the successful execution of their M&A strategy – with synergies materialising faster than expected. The Woundcare fix appears to be working, removing a previous headwind. The confidence in hitting full-year forecasts feels well-founded based on this H1 performance and the stated momentum. It paints a picture of a specialist medtech player efficiently stitching together its acquisitions and core operations to drive value. One to watch when those interims drop in September.
